Skip to main content
SpringerLink
Log in

Palivizumab

  • Chapter
  • First Online:
Book cover Adverse Events with Biomedicines

  • 1224 Accesses

Abstract

Palivizumab (Synagis®, MedImmune, Abbott) is a recombinant humanized IgG1k monoclonal antibody (MEDI-493) directed to specific surface proteins of the respiratory syncytial virus (RSV).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Palivizumab (Synagis®) BLA 971359 Clinical Review FDA June 1998

    Google Scholar 

  2. Palivizumab (Synagis®) WC500056731 Scientific Discussion EMEA, Oct 2004

    Google Scholar 

  3. Palivizumab (Synagis®) Product Information MedImmune, Apr 2012

    Google Scholar 

  4. Palivizumab (Synagis®) WC500056908 EPAR Annex I EMEA, Nov 2012

    Google Scholar 

  5. Navas L, Wang E, de Carvalho V et al (1992) Improved outcome of respiratory syncytial virus infection in high-risk hospitalized population of Canadian children. Pediatric Investigator Collaborative Network on Infections in Canada. J Pediatr 121:348–354

    Article  PubMed  CAS  Google Scholar 

  6. IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102:531–537

    Article  Google Scholar 

  7. AAPC (1998) Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics 102:1211–1216

    Article  Google Scholar 

  8. Palivizumab (Synagis®) WC500131776 CHMP Assessment Report EMEA, Aug 2012

    Google Scholar 

  9. Turti TV, Baibarina EN, Degtiareva EA et al (2012) A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation. BMC Res Notes 5:484. doi:10.1186/1756-0500-5-484

    Article  PubMed  CAS  Google Scholar 

  10. Cecchia PA, Nalysnyk L, Fernandes AW et al (2011) Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr Crit Care Med 12:580–588

    Article  Google Scholar 

  11. Paes B, Mitchell I, Li A et al (2012) Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr 171:833–841

    Article  PubMed  CAS  Google Scholar 

  12. Mori M, Kawashima H, Nakamura H et al (2011) Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan. J Infect Chemother 17:254–263

    Article  PubMed  CAS  Google Scholar 

  13. Taylor RS (2012) CARESS The Canadian registry of palivizumab. Pediatr Infect Dis J 31:212–213

    Article  PubMed  Google Scholar 

  14. Carbonell-Estrany X (2003) Palivizumab outcomes registry data from Spain: infección respiratoria infantile por virus respiratorio sincitial (IRIS) study group. Pediatr Infect Dis J 22:S55–S57

    PubMed  Google Scholar 

  15. Manzoni P, Paes B, Resch B et al (2012) High risk for RSV bronchiolitis in late preterm’s and selected infants affected by rare disorders: a dilemma of specific prevention. Early Human Dev 88:S34–S41

    Article  Google Scholar 

  16. Speer ME, Fernandes CJ, Boron M et al (2008) Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J 27:559–561

    Article  PubMed  Google Scholar 

  17. Robinson KA, Odelola OA, Saldanha IJ et al (2012) Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis (Review). The Cochrane Library 2:1–22

    Google Scholar 

  18. Prescott WA, Hutchinson DJ (2011) Respiratory syncytial virus prophylaxis in special populations: is it something worth considering in cystic fibrosis and immunosuppression? JPPT 16:77–86

    PubMed  Google Scholar 

  19. Boeckh M, Berrey MM, Bowden RA et al (2001) Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. JID 184:350–354

    Article  PubMed  CAS  Google Scholar 

  20. Kassis C, Champlin RE, Hachem RY et al (2010) Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab. Biol Blood Marrow Transplant 16:1265–1271

    Article  PubMed  CAS  Google Scholar 

  21. De Fontbrune FS, Robin M, Porcher R et al (2007) Palivizumab treatment of respiratory syncytial virus infection after allogeneic hemopoietic stem cell transplantation. Clin Infect Dis 45:1019–1024

    Article  PubMed  Google Scholar 

  22. Santos RP, Chao J, Nepo AG et al (2012) The use of intravenous palivizumab for treatment of persistent RSV infection in children with leukemia. Pediatrics 130:e1695–e1699

    Article  PubMed  Google Scholar 

  23. Danziger-Isakov LA, Arslan D, Sweet S et al (2012) RSV prevention and treatment in pediatric lung transplant patients: a survey of current practices among the International Pediatric Transplant Collaborative. Pediatr Transpl 16:638–644

    Article  CAS  Google Scholar 

  24. Zhu Q, Patel NK, McAuliffe JM et al (2012) Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab. JID 205:635–638

    Article  PubMed  CAS  Google Scholar 

  25. Fernandez P, Trenholme A, Abarca K et al (2010) A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr 10:38–51

    Article  PubMed  Google Scholar 

  26. Carbonell-Estrany X, Simões EAF, Dagan R et al (2010) Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 125:e35–e51

    Article  PubMed  Google Scholar 

  27. Feltes TF, Sondheimer HM, Tulloh RMR et al (2011) A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediat Res 70:186–191

    Article  PubMed  CAS  Google Scholar 

  28. Mejías A and Ramilo O (2008) Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. Biologics: Targets Ther 2:433–439

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Verona, Verona, Italy

    Giuseppe Tridente

Authors
  1. Giuseppe Tridente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Tridente .

1 Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLS 61 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Tridente, G. (2014). Palivizumab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_31

Download citation

Publish with us

Policies and ethics

Search

Navigation